Waters Corporation is a global leader in analytical laboratory instrumentation and software, specializing in the development and manufacture of advanced technologies for liquid chromatography, mass spectrometry, and thermal analysis. The company serves a diverse range of industries, including pharmaceuticals, biotechnology, food and beverage, environmental, and academic research, providing essential tools for scientific research, quality control, and regulatory compliance. With a strong emphasis on innovation and precision, Waters is dedicated to helping scientists and researchers optimize their analytical processes and obtain reliable, high-quality data to further their work. Read More
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.
Shares of scientific instruments company Waters Corporation (NYSE:WAT)
jumped 8.2% in the morning session after it reported mixed third-quarter 2025 results where a strong revenue performance outweighed a miss on profitability. The company announced sales of $799.9 million, up 8% year on year and beating Wall Street estimates by 2.4%. This top-line strength was driven by an 8% increase in organic revenue, which also surpassed expectations. However, the quarter was not without its challenges. Waters reported GAAP earnings per share of $2.50, which was 14.7% below what analysts had projected. The company's profitability also came under pressure, with its operating margin contracting to 24% from 28.5% in the same period last year. Looking ahead, Waters guided for fourth-quarter revenue of around $926.8 million, which was in line with analyst forecasts. Investors appeared to focus on the strong sales growth and stable outlook, choosing to overlook the weaker-than-expected earnings for the quarter.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Scientific instruments company Waters Corporation (NYSE:WAT) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 8% year on year to $799.9 million. The company expects next quarter’s revenue to be around $926.8 million, close to analysts’ estimates. Its GAAP profit of $2.50 per share was 14.7% below analysts’ consensus estimates.
Scientific instruments company Waters Corporation (NYSE:WAT)
will be reporting earnings this Tuesday before market hours. Here’s what you need to know.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Shares of scientific instruments company Waters Corporation (NYSE:WAT)
jumped 3.2% in the morning session after Rothschild & Co initiated coverage on the stock with a 'Buy' rating and a $390 price target.
Washington D.C. – The Federal Reserve has sent clear signals of a continued dovish pivot, with Chair Jerome Powell indicating the likelihood of two additional quarter-point interest rate cuts before the close of 2025. This aggressive stance comes on the heels of a September rate reduction and is primarily driven
Waters Corporation has been treading water for the past six months, recording a small return of 3.5% while holding steady at $318.35. The stock also fell short of the S&P 500’s 34.7% gain during that period.
New York, NY – September 30, 2025 – AMN Healthcare Services (NYSE: AMN), a leading provider of healthcare staffing solutions, witnessed a significant upward movement in its stock today, reflecting a broader market optimism rippling through the healthcare sector. While AMN's direct stock drivers often stem from company-specific operational successes, today's surge
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing agreement reached between the White House and a major pharmaceutical player, Pfizer (NYSE: PFE). This development has been widely interpreted by investors as
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped the upside for healthcare stocks lately as the industry’s flat return over the past six months has trailed the S&P 500’s 17.4% gain.
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
